HAYA Therapeutics and Eli Lilly Partner to Discover Novel Regulatory Genome Targets for Obesity and Other Metabolic Conditions
Shots:
- HAYA Therapeutics & Eli Lilly have entered into a multi-year agreement to discover regulatory genome derived RNA-based drug targets, focusing on obesity and other metabolic disorders
- The alliance will leverage HAYA’s regulatory genome discovery platform that will allow the identification, characterization & validation of lncRNA targets (precisely for tissues, diseases & cells) for the same
- As per the agreement, Lilly will pay an undisclosed upfront (incl. equity investment), up to $1B pre-clinical, clinical & commercial milestones plus sales-based royalties
Ref: HAYA Therapeutics | Image: Eli Lilly & HAYA Therapeutics
Related News:- Eli Lilly Reports the P-III (SUMMIT) Trial Data of Tirzepatide to Treat Heart Failure with Preserved Ejection Fraction and Obesity
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
